Notice Concerning New Management Structure
Tokyo, Japan and Cambridge, UK, 25 March 2026 - Nxera Pharma Co., Ltd. ("Nxera" or "the Company"; TSE 4565) today announces that at the 36th Annual General Meeting of Shareholders held on March 25, 2026, and at the subsequent meeting of the Board of Directors, the Company resolved its new management structure as set forth below. Chris Cargill, President s CEO of Nxera Pharma, said: "I am very pleased that Mr. Morooka was newly elected as a Director of the Company at today's Annual General Meeting of Shareholders. We expect that Mr. Morooka will contribute to the promotion of the Company's growth strategy and further strengthening of corporate governance, leveraging extensive experience and expertise in corporate management, technology and RCD-driven innovation, business strategy and marketing. At the same time, I would like to express my sincere gratitude to the retiring Directors for their many years of dedicated support and significant contributions to the Company's development" New Officer Structure (Effective March 25, 2026)-
Directors
Mr. Chris Cargill, Representative Executive Officer (re-appointed) Dr. David Roblin, External Director (re-appointed)
Mr. Rolf Soderstrom, External Director (re-appointed) Ms. Eiko Tomita, External Director (re-appointed) Ms. Naoko Shimura, External Director (re-appointed) Ms. Nicola Rabson, External Director (re-appointed)
Mr. Takeo Morooka, External Director (newly appointed)
- Executives
President & Chief Executive Officer Chris Cargill (re-appointed)
EVP, Chief Financial Officer Hironoshin Nomura (re-appointed)
EVP, Chief Operating Officer Toshihiro Maeda (re-appointed) EVP, President of Nxera UK, Chief Scientific Officer Patrik Foerch (re-appointed) EVP, Chief Accounting Officer Kieran Johnson (re-appointed)
EVP, Chief of Staff Candelle Chong (re-appointed)
EVP, Chief Legal Officer Mariko Nakafuji (re-appointed)
-END-
About Nxera PharmaNxera Pharma is a technology powered biopharma company in pursuit of new specialty medicines to improve the lives of patients with unmet needs in Japan and globally. The Company has built an agile, new-generation commercial business in Japan to develop and commercialize innovative medicines, including several launched products, to address this high-value, large and growing market and those in the broader APAC region. In addition, the Company is advancing an extensive pipeline internally and in partnership with leading pharma and biotech companies powered by its unique NxWave™ GPCR structure-based drug discovery platform. Nxera Pharma operates at key locations in Tokyo and Osaka (Japan), London and Cambridge (UK), Basel (Switzerland) and Seoul (South Korea) and is listed on the Tokyo Stock Exchange (ticker: 4565).
For more information, please visit https://www.nxera.life
LinkedIn: @NxeraPharma | X: @NxeraPharma | YouTube: @NxeraPharma
Enquiries: Media and Investor RelationsShinya Tsuzuki, VP, Head of Investor Relations Maya Bennison, Communications Manager
+81 (0)3 5962 5718 | +44 (0)1223 949390 |IR@Nxera.life
MEDiSTRAVA (for International Media)Mark Swallow, Frazer Hall, Erica Hollingsworth
+44 (0)203 928 6900 | Nxera@medistrava.com
Forward-looking statementsThis press release contains forward-looking statements, including statements about the discovery, development, and commercialization of products. Various risks may cause Nxera Pharma Group's actual results to differ materially from those expressed or implied by the forward looking statements, including: adverse results in clinical development programs; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialize products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialization activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
2 of 2